Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1257-1271

  Hoeben, Bianca A W ^a   Bussink, Johan ^a   Troost, Esther G C ^b   Oyen, Wim J G ^a   Kaanders, Johannes H A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL]1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL F 18; 3' FLUOROTHYMIDINE F 18; CETUXIMAB; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; ETANIDAZOLE; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; RADIOSENSITIZING AGENT; TRACER; UNCLASSIFIED DRUG; NITROIMIDAZOLE;

CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; IMAGE ANALYSIS; INTENSITY MODULATED RADIATION THERAPY; MOLECULAR IMAGING; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIOSENSITIVITY; REPRODUCIBILITY; REVIEW; STANDARDIZATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; ARTICLE; BIOLOGY GUIDED ADAPTIVE RADIOTHERAPY; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL PRACTICE; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; HEAD AND NECK CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR VOLUME;

ADAPTATION, BIOLOGICAL; ANIMALS; BIOLOGY; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84884547357     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.812799     Document Type: Review

References (141)

1. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011;100:33-40
2. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datAfrom a phase 3 randomised trial, and relation between cetuximabinduced rasHand survival. Lancet Oncol 2010;11:21-8
3. Pignon JP, Le Maitre A, Maillard E, Bourhis J. M eta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14
4. Gregoire V, Jeraj R, Lee JA, O 'Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: Conformal, tailored, and adaptive? Lancet Oncol 2012;13:e292-300
5. Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 2008;27:545-54
6. Busk M, Horsman M R, Kristjansen P E, Van Der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008;122:2726-34
7. Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T, Sasabe E, et al. Correlation of metabolism/ hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral PathoLoral Radiol 2012;113:464-71
8. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31
9. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 2009;35:699-705
10. Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates witHakt pathway activity but is not predictive of clinicaLoutcome during mTOR inhibitor therapy. J Clin Oncol 2009;27:2697-704
11. Nguyen QD, Perumal M, Waldman T A, Aboagye EO. Glucose metabolism measured by [(1)(8)F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. TransLoncol 2011;4:241-8
12. Deron P, Vangestel C, Goethals I, De Potter A, Peeters M, Vermeersch H, et al. FDGuptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis. Nuklearmedizin 2011;50:15-21
13. Delouya G, Igidbashian L, Houle A, Belair M, Boucher L, Cohade C, et al. (1)(8)F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer. Radiother Oncol 2011;101:362-8
14. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-15
15. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: A meta-analysis. JNCI 2008;100:712-20
16. Nishioka T, Shiga T, ShiratOh, Tsukamoto E, Tsuchiya K, Kato T, et al. Image fusion between 18FDG-PET and MRI/ CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002;53:1051-7
17. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: ComparisoNat CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100
18. Geets X, Daisne J F, Tomsej M, Duprez T, Lonneux M, Gregoire V. Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngolaryngeal squamous cell carcinoma: Comparison between preand per-treatment studies. Radiother Oncol 2006;78:291-7
19. Riegel AC, Berson AM, Destian S, Ng T, TenAl B, Mitnick RJ, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 2006;65:726-32
20. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradientbased method for segmenting FDG-PET images: Methodology and validation. Eur J Nucl Med MoLimaging 2007;34:1427-38
21. Ashamalla H, Guirgius A, Bieniek E, Rafla S, Evola A, Goswami G, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumor volume for head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:388-95
22. Breen SL, Publicover J, De Silva S, Pond G, Brock K, O'Sullivan B, et al. Intraobserver and interobserver variability iNgTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:763-70
23. Deantonio L, Beldi D, Gambaro G, Loi G, Brambilla M, Inglese E, et al. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 2008;3:29
24. Thiagarajan A, Caria N, Schoder H, Iyer NG, Wolden S, Wong RJ, et al. Target volume delineation in oropharyngeal cancer: Impact of PET, MRI, and physicaLexamination. Int J Radiat Oncol Biol Phys 2012;83:220-7
25. Perez-RomasantAlA, Bellon-Guardia M, Torres-Donaire J, Lozano-Martin E, Sanz-Martin M, Velasco-Jimenez J. Tumor volume delineation in head and neck cancer with 18-fl uor-fluorodeoxiglucose positron emission tomography: Adaptive thresholding method applied to primary tumors and metastatic lymph nodes. Clin TransLoncol 2013;15:283-93
26. Moule RN, Kayani I, Moinuddin SA, Meer K, Lemon C, Goodchild K, et al. The potential advantages of (18)FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer. Radiother Oncol 2010;97:189-93
27. van Dalen J A, Hoffmann AL, Dicken V, Vogel W V, Wiering B, Ruers TJ, et al. A noveLiterative method for lesion delineation and volumetric quantifi cation with FDG PET. Nucl Med Commun 2007;28:485-93
28. Geets X, Tomsej M, Lee JA, Duprez T, Coche E, Cosnard G, et al. Adaptive biologicaLimage-guideDiMRT witHanatomic and functionaLimaging in pharyngo-laryngeal tumors: Impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007;85:105-15
29. Castadot P, Geets X, Lee J A, Christian N, Gregoire V. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother Oncol 2010;95:209-17
30. Han D, Bayouth J, Song Q, Taurani A, Sonka M, Buatti J, et al. Globally optimal tumor segmentation in PET-CT images: A graph-based co-segmentation method. Inf Process MeDimaging 2011;22:245-56
31. Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, et al. Reproducibility of 18FFDG and 3 ′-deoxy-3 ′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med 2010;51:1368-76
32. Schinagl DA, Vogel W V, Hoffmann AL, van Dalen JA, Oyen WJ, Kaanders JH. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume defi nition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:1282-9
33. Caldas-Magalhaes J, Kasperts N, Kooij N, Van Den Berg CA, Terhaard CH, Raaijmakers CP, et al. Validation of imaging with pathology in laryngeal cancer: Accuracy of the registration methodology. Int J Radiat Oncol Biol Phys 2012;82:e289-98
34. Zaidi H, AbdolIm, Fuentes CL, El Naqa IM. C omparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med MoLimaging 2012;39:881-91
35. Schinagl DA, Hoffmann AL, Vogel W V, van Dalen JA, Verstappen SM, Oyen W, et al. Can FDG-PET assist in radiotherapy target volume defi nition of metastatic lymph nodes in head-and-neck cancer? Radiat Oncol 2009;91:95-100
36. Schwartz D L, ForDe C, Rajendran J, Yueh B, Coltrera M D, Virgin J, et al. FDG-PET/CT-guideDintensity modulated head and neck radiotherapy: A pilot investigation. Head Neck 2005;27:478-87
37. Vanderstraeten B, Duthoy W, De Gersem W, De Neve W, Thierens H. [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxeLintensity-baseDintensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006;79:249-58
38. Madani I, Duthoy W, Derie C, De Gersem W, Boterberg T, Saerens M, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-35
39. Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann C, Davis JB, et al. PET/CT staging followed by intensitymodulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: A matched-pair comparison. Radiat Oncol 2007;2:22
40. Vernon M R, MaheshwarIm, Schultz C J, Michel M A, Wong SJ, Campbell BH, et al. ClinicaLoutcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 2008;70:678-84
41. Hentschel M, Appold S, Schreiber A, Abramyuk A, Abolmaali N, Kotzerke J, et al. Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy. Int J Radiat Biol 2009;85:796-804
42. Moule RN, Kayani I, Prior T, Lemon C, Goodchild K, Sanghera B, et al. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomographybased target volume delineation in radiotherapy planning of head and neck cancer. Clin Oncol (R Coll Radiol) 2011;23:364-71
43. Bentzen S M. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005;6:112-7
44. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, et al. Maximum tolerated dose in a phase I triaLon adaptive dose painting by numbers for head and neck cancer. Radiother Oncol 2011;101:351-5
45. Schwartz DL, Garden AS, Thomas J, Chen Y, Zhang Y, Lewin J, et al. Adaptive radiotherapy for head-and-neck cancer: Initial clinicaLoutcomes from a prospective trial. Int J Radiat Oncol Biol Phys 2012;83:986-93
46. Kim YS, Roh J-L, Kim M R, Kim J S, Choi S-H, Nam S Y, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007;48:752-7
47. Linecker A, Kermer C, Sulzbacher I, Angelberger P, Kletter K, Dudczak R, et al. Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 2008;47:80-5
48. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010;49:201-8
49. Dibble E H, Alvarez AC, Truong M T, Mercier G, Cook E F, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J Nucl Med 2012;53:709-15
50. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. C an FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med MoLimaging 2011;38:1449-58
51. Hoshikawa H, Kishino T, Nishiyama Y, Yamamoto Y, YonezakIm, Mori N. Early prediction of local controLin head and neck cancer after chemoradiotherapy by FDGPET . Nucl Med Commun 2011;32:684-9
52. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the folloWup of head and neck squamous cell carcinomAfollowing radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-22
53. Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50(SUPPL. 1):74S-88S.
54. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-35
55. Hentschel M, Appold S, Schreiber A, Abolmaali N, Abramyuk A, Dorr W, et al. Early FDG PET at 10 or 20 GYunder chemoradiotherapy is prognostic for locoregional control and overall survivaLin patients with head and neck cancer. Eur J Nucl Med MoLimaging 2011;38:1203-11
56. Castaldi P, Rufi ni V, Bussu F, Micciche F, Dinapoli N, Autorino R, et al. Can " early " and " late " (18)F-FDG PET-CT be used as prognostic factors for the clinicaLoutcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012;103:63-8
57. Huang SH, Chien CY, Lin WC, Fang FM, Wang PW, Lui CC, et al. A comparative study of fused FDG PET/ MRI, PET/CT, MRI, and CT imaging for assessing surrounding tissue invasion of advanced buccal squamous cell carcinoma. Clin Nucl Med 2011;36:518-25
58. Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R. Impact of [(1)(8)F]FDG PET imaging parameters on automatic tumour delineation: Need for improved tumour delineation methodology. Eur J Nucl Med MoLimaging 2011;38:2136-44
59. Lee J A. S egmentation of positron emission tomography images: Some recommendations for target delineation in radiation oncology. Radiother Oncol 2010;96:302-7
60. Boellaard R. S tandards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(SUPPL. 1):11S-20S.
61. Soto DE, Kessler M L, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol 2008;89:13-8
62. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9
63. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9(Suppl5):10-7
64. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24
65. Kaanders J H, Wijffels K I, Marres HA, Ljungkvist AS, Pop LA, Van Den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74
66. Janssens G O, Rademakers S E, Terhaard C H, Doornaert PA, Bijl HP, Van Den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 2012;30:1777-83
67. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46
68. Overgaard J. Hypoxic modifi cation of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32
69. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specifi c assays: The basis for biologically adapteDindividualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007;83:389-97
70. Busk M, Horsman MR, Jakobsen S, Bussink J, Van Der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med MoLimaging 2008;35:2294-303
71. Rajendran J G, Mankoff D A, O 'Sullivan F, Peterson L M, Schwartz DL, ConraDeU, et al. Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F] fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52
72. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304
73. Troost EG, Laverman P, Philippens ME, Lok J, Van Der Kogel AJ, Oyen WJ, et al. Correlation of [(18)F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med MoLimaging 2008;35:1803-11
74. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: Validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113
75. Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, et al. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol 2010;49:934-40
76. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212
77. Abolmaali N, Haase R, Koch A, Zips D, Steinbach J, Baumann M, et al. Two or four hour [18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011;50:22-7
78. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-24
79. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S, et al. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51
80. Mahy P, Geets X, Lonneux M, Leveque P, Christian N, De Bast M, et al. Determination of tumour hypoxia with [(18)F]EF3 in patients with head and neck tumours: A phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med MoLimaging 2008;35:1282-9
81. Busk M, Horsman M R, Jakobsen S, Keiding S, Van Der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: A comparative study involving microPET, autoradiography, PO2-polarography, and fl uorescence microscopy. Int J Radiat Oncol Biol Phys 2008;70:1202-12
82. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med MoLimaging 2007;34:1566-75
83. Postema E J, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN, et al. Initial results of hypoxia imaginGusing 1-alpha-D:-(5-deoxy-5-[(18)F]-fluoroarabinofuranosyl)-2-nitroimidazole ((18)F-FAZA). Eur J Nucl Med MoLimaging 2009;36:1565-73
84. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20
85. Chen L, Zhang Z, Kolb H C, Walsh J C, Zhang J, Guan Y.(1)(8)F-HX4 hypoxia imaging with PET/CT in head and neck cancer: A comparison with (1)(8)F-FMIS O. Nucl Med Commun 2012;33:1096-102
86. Lehtio K, Oikonen V, Gronroos T, Eskola O, Kalliokoski K, Bergman J, et al. Imaging of blood flow and hypoxia in head and neck cancer: InitiaLevaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med 2001;42:1643-52
87. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60
88. Holland J P, Lewis J S, Dehdashti F. A ssessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med MoLimaging 2009;53:193-200
89. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study. Ann Nucl Med 2011;25:339-45
90. Troost EG, Bussink J, Kaanders JH, van EJ, Peters JP, Rijken PF, et al. Comparison of different methods of CAIX quantifi cation in relation tOhypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194-9
91. Hoeben BA, Kaanders JH, FransseNgM, Troost EG, Rijken PF, Oosterwijk E, et al. PET of hypoxia with 89Zrlabeled cG250-F(ab ′) 2 in head and neck tumors. J Nucl Med 2010;51:1076-83
92. Ljungkvist AS, Bussink J, Kaanders J H, Rijken P F, Begg AC, Raleigh JA, et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005;62:1157-68
93. Monnich D, Troost EG, Kaanders JH, Oyen WJ, Alber M, Thorwarth D. Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys Med Biol 2011;56:2045-57
94. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42
95. Okamoto S, Shiga T, Yasuda K, Ito Y M, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201-7
96. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guideDintensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82
97. Dalah E, Bradley D, Nisbet A. Simulation of tissue activity curves of (64)Cu-ATSM for sub-target volume delineation in radiotherapy. Phys Med Biol 2010;55:681-94
98. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol 2003;48:N31-5
99. Rajendran J G, Hendrickson KR, Spence AM, MuzIm, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med MoLimaging 2006;33(SUPPL. 13):44-53
100. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51
101. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guideDintensity-modulated radiotherapy for head and neck cancer: Afeasibility study. Int J Radiat Oncol Biol Phys 2008;70:2-13
102. Choi W, Lee S W, Park S H, Ryu J S, Oh S J, Im K C, et al. Planning study for available dose of hypoxic tumor volume using fl uorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol 2010;97:176-82
103. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxiainduced treatment resistance. Radiother Oncol 2011;101:369-75
104. Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: A biological modeling study. Acta OncoLepub 2013 Jan 15
105. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, et al. The infl uence of changes in tumor hypoxia on dosepainting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008;70:1219-28
106. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300
107. Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol 2012;51:222-30
108. Korreman SS, Ulrich S, Bowen S, Deveau M, Bentzen SM, Jeraj R. Feasibility of dose paintinGusing volumetric modulated arc optimization and delivery. Acta Oncol 2010;49:964-71
109. Thorwarth D, Eschmann S M, Paulsen F, Alber M. A modeLof reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 2007;68:515-21
110. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60
111. Rajendran JG, Schwartz DL, O 'Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41
112. Rischin D, Hicks R J, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic signifi cance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients witHadvanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104
113. KikuchIm, Yamane T, Shinohara S, Fujiwara K, Hori S Y, Tona Y, et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011;25:625-33
114. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, et al. Prospective triaLincorporating pre-/mid-treatment [(18)F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;75:101-8
115. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective triaLof hypoxiaspecifi c PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8
116. Rischin D, Peters L J, O 'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III triaLof the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95
117. Kim J J, Tannock I F. R epopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005;5:516-25
118. Fu KK, Pajak T F, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16
119. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40
120. Bonner J A, Harari PM, Giralt J, Azarnia N, Shin D M, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEJM 2006;354:567-78
121. Rütten H, Pop L A, Janssens G O, Takes R P, Knuijt S, Rooijakkers AF, et al. Long-term outcome and morbidity after treatment witHaccelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: Results of a multidisciplinary late morbidity clinic. Int J Radiat Oncol Biol Phys 2011;81:923-9
122. Shields AF, Grierson J R, Dohmen B M, Machulla H J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6
123. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7
124. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantifi cation of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res 2005;65:10104-12
125. Yap C S, Czernin J, Fishbein M C, Cameron R B, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401
126. Cobben DC, Elsinga PH, Suurmeijer A J, Vaalburg W, Maas B, Jager PL, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3 ′-fluoro-3 ′-deoxy-L-thymidine. Clin Cancer Res 2004;10:1685-90
127. Troost EG, Bussink J, Slootweg PJ, Peeters WJ, Merkx MA, Van Der Kogel AJ, et al. Histopathologic validation of 3 ′-deoxy-3 ′-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl Med 2010;51:713-9
128. Troost E G, Vogel W V, Merkx M A, Slootweg P J, Marres HA, Peeters WJ, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-35
129. Delangen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3 ′-deoxy-3 ′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med MoLimaging 2009;36:389-95
130. Molthoff C F, Klabbers B M, Berkhof J, Felten JT, vaNgelder M, Windhorst AD, et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: Comparison of 2 ′-deoxy-2 ′-[18F]fluoro-D-glucose (FDG) and 3 ′-[18F]fluoro-3 ′-deoxythymidine (FLT). MoLimaging Biol 2007;9:340-7
131. Troost E G, Bussink J, Hoffmann AL, Boerman O C, Oyen WJ, Kaanders JH. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74
132. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson T J, Watkins GL, Schultz MK, et al. Kinetic analysis of 3 ′-deoxy-3 ′-(18) F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before anDearly after initiation of chemoradiation therapy. J Nucl Med 2009;50:1028-35
133. Barney B M, Lowe V, Okuno S H, Kep B J, Jacobson MS, Price KA, et al. A pilot study comparing FLT-PET and FDG-PET in the evaluation of response to cetuximab and radiation therapy in advanced head and neck malignancies. Nucl Med Radiat Ther 2012;3:1
134. Hoeben BA, Troost EG, Span PN, Herpen CM, Bussink J, Oyen W, et al. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 2013;54:532-40
135. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3 ′-deoxy-3 ′-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med 2012;53:1521-7
136. Hoshikawa H, Mori T, Kishino T, Yamamoto Y, Inamoto R, Akiyama K, et al. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy. Ann Nucl Med 2013;27:363-70
137. McKinleYeT, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, et al. Limits of [(18)F]-FLT PET as a biomarker of proliferation in oncology. PloS One 2013;8:e58938
138. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functionaLimaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrastenhanced MRI. J Nucl Med 2009;50:1020-7
139. Thorwarth D, Beyer T, Boellaard R, De Ruysscher D, Grgic A, Lee JA, et al. Integration of FDG-PET/CT into external beam radiation therapy planning: Technical aspects and recommendations on methodological approaches. Nuklearmedizin 2012;51:140-53
140. McCall KC, Barbee DL, Kissick MW, Jeraj R. PET imaging for the quantifi cation of biologically heterogeneous tumours: Measuring the effect of relative position on image-based quantifi cation of dose-painting targets. Phys Med Biol 2010;55:2789-806
141. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: Voxel size matters. Acta Oncol 2008;47:1201-10